Acinetobacter johnsonii is a common member of the Acinetobacter genus and can be found in various environmental niches, including soil, water, and hospital settings. However, A. johnsonii has become an emerging human pathogen, causing a range of infections, including wound infections, sepsis, and pneumonia.

One of the toxins produced by A. johnsonii is ChpA, a type VI secretion system (T6SS) effector protein. ChpA has been shown to induce cell death in mammalian cells, and its activity has been linked to virulence in A. johnsonii infections.

Another toxin produced by A. johnsonii is Txe-YoeB, a member of the Txe-YoeB family addiction module toxins. Txe-YoeB has been implicated in stress response, biofilm formation, and antibiotic resistance in A. johnsonii. This toxin has also been shown to have activity against a range of bacterial species, including other members of the Acinetobacter genus.

Finally, A. johnsonii produces a Zeta family protein, which has been shown to induce programmed cell death in E. coli. The exact role of this toxin in A. johnsonii pathogenesis is still being studied, but it has been suggested that it may be involved in A. johnsonii’s ability to survive and persist in various environments.

Understanding the mechanisms by which A. johnsonii produces and uses toxins like ChpA, Txe-YoeB, and Zeta Family Proteins is essential for developing new approaches to control or treat infections caused by this emerging pathogen.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, successful recombinant protein expression in heterologous expression systems depends on various factors, including codon preference, RNA secondary structure, and GC content. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins. Compared to pre-optimization, more experimental results demonstrated that the expression level was dramatically increased, ranging from two to a hundred times depending on the gene.

Acinetobacter johnsonii cDNA and recombinant antigen can be applied in various biomedical research fields, such as vaccine development, pathogenesis studies, and diagnostics. The cDNA and its recombinant antigen can be used to create a specific gene probe for Acinetobacter johnsonii, which can be used to identify and detect the pathogen in clinical samples. Furthermore, the cDNA and recombinant antigen can be used to develop a subunit vaccine against Acinetobacter johnsonii. The vaccine can be used to protect individuals from infection with the pathogen. Additionally, the cDNA and recombinant antigen can be used to study the pathogenesis and transmission of the pathogen. This knowledge can be used to design better control strategies and treatments for the infections caused by Acinetobacter johnsonii.